aTyr Pharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
aTyr Pharma (ATYR), a clinical stage biotechnology company, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's CEO, Sanjay S. Shukla, will deliver a corporate presentation on Thursday, January 16, 2025, at 8:15am PST in San Francisco.
The company specializes in developing first-in-class medicines from its proprietary tRNA synthetase platform. Their lead therapeutic candidate, efzofitimod, is a first-in-class biologic immunomodulator being developed for interstitial lung disease treatment. The presentation will be webcasted and available on the company's website for at least 30 days afterward.
aTyr's platform focuses on unlocking therapeutic intervention points through signaling pathways driven by domains derived from all 20 tRNA synthetases, which are ancient proteins that have evolved to regulate diverse extracellular pathways in humans.
aTyr Pharma (ATYR), un'azienda biotecnologica in fase clinica, ha annunciato la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference. Il CEO dell'azienda, Sanjay S. Shukla, terrà una presentazione aziendale giovedì 16 gennaio 2025, alle 8:15 PST a San Francisco.
L'azienda si specializza nello sviluppo di farmaci innovativi dalla sua piattaforma proprietaria di tRNA sintetasi. Il loro principale candidato terapeutico, efzofitimod, è un immunomodulatore biologico di prima classe in fase di sviluppo per il trattamento delle malattie polmonari interstiziali. La presentazione sarà trasmessa in diretta e disponibile sul sito web dell'azienda per almeno 30 giorni dopo l'evento.
La piattaforma di aTyr si concentra sull'apertura di punti di intervento terapeutico attraverso le vie di segnalazione guidate da domini derivati da tutte e 20 le tRNA sintetasi, che sono proteine antiche evolute per regolare diverse vie extracellulari negli esseri umani.
aTyr Pharma (ATYR), una empresa biotecnológica en etapa clínica, ha anunciado su participación en la 43ª Conferencia Anual de Salud de J.P. Morgan. El CEO de la empresa, Sanjay S. Shukla, ofrecerá una presentación corporativa el jueves 16 de enero de 2025, a las 8:15 am PST en San Francisco.
La empresa se especializa en el desarrollo de medicamentos innovadores a partir de su plataforma propietaria de tRNA sintetasa. Su principal candidato terapéutico, efzofitimod, es un inmunomodulador biológico de primera clase que se desarrolla para el tratamiento de enfermedades pulmonares intersticiales. La presentación será transmitida en línea y estará disponible en el sitio web de la empresa durante al menos 30 días después.
La plataforma de aTyr se centra en desbloquear puntos de intervención terapéutica a través de vías de señalización impulsadas por dominios derivados de las 20 tRNA sintetasas, que son proteínas antiguas que han evolucionado para regular diversas rutas extracelulares en humanos.
aTyr Pharma (ATYR), 임상 단계의 생명공학 회사, 가 제43회 연례 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 회사의 CEO인 Sanjay S. Shukla는 2025년 1월 16일 목요일 오전 8:15 PST에 샌프란시스코에서 기업 발표를 할 예정입니다.
회사는 자사의 독점 tRNA 합성효소 플랫폼을 통해 최초의 혁신적인 약물을 개발하는 데 전문화되고 있습니다. 그들의 주요 치료 후보 물질인 efzofitimod는 간질성 폐질환 치료를 위해 개발되고 있는 최초의 생물학적 면역 조절제입니다. 발표는 웹캐스트로 진행되며 발표 후 최소 30일 동안 회사 웹사이트에서 볼 수 있습니다.
aTyr의 플랫폼은 20가지 tRNA 합성효소에서 유래된 도메인에 의해 주도되는 신호 전달 경로를 통해 치료 개입 지점을 잠금 해제하는 데 중점을 둡니다. 이들은 인간의 다양한 세포 외 경로를 조절하기 위해 진화된 고대 단백질입니다.
aTyr Pharma (ATYR), une entreprise de biotechnologie en phase clinique, a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan Healthcare. Le PDG de l'entreprise, Sanjay S. Shukla, présentera une présentation d'entreprise le jeudi 16 janvier 2025, à 8h15 PST à San Francisco.
L'entreprise est spécialisée dans le développement de médicaments de première classe à partir de sa plateforme propriétaire de tRNA synthétase. Leur principal candidat thérapeutique, efzofitimod, est un immunomodulateur biologique de première classe en cours de développement pour le traitement des maladies pulmonaires interstitielles. La présentation sera diffusée en direct et sera disponible sur le site web de l'entreprise pendant au moins 30 jours après.
La plateforme d'aTyr se concentre sur le déblocage des points d'intervention thérapeutique à travers des voies de signalisation dérivées de tous les 20 tRNA synthétases, qui sont des protéines anciennes ayant évolué pour réguler diverses voies extracellulaires chez l'homme.
aTyr Pharma (ATYR), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an der 43. Jahreskonferenz von J.P. Morgan Healthcare bekannt gegeben. Der CEO des Unternehmens, Sanjay S. Shukla, wird am Donnerstag, den 16. Januar 2025, um 8:15 Uhr PST in San Francisco eine Unternehmenspräsentation halten.
Das Unternehmen ist auf die Entwicklung von erstklassigen Medikamenten aus seiner proprietären tRNA-Synthetase-Plattform spezialisiert. Ihr Hauptkandidat, efzofitimod, ist ein erstklassiger biologischer Immunmodulator, der zur Behandlung von interstitiellen Lungenerkrankungen entwickelt wird. Die Präsentation wird im Internet übertragen und ist mindestens 30 Tage lang auf der Website des Unternehmens verfügbar.
Die Plattform von aTyr konzentriert sich darauf, therapeutische Interventionspunkte durch Signalwege zu erschließen, die von Domänen abgeleitet sind, die aus allen 20 tRNA-Synthetasen stammen, die uralte Proteine sind, die sich entwickelt haben, um verschiedene extrazelluläre Wege im Menschen zu regulieren.
- None.
- None.
SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is scheduled to take place January 13 – 16, 2025, in San Francisco, CA.
Details of the presentation appear below:
Conference: 43rd Annual J.P. Morgan Healthcare Conference
Date: Thursday, January 16, 2025
Time: 8:15am PST
Location: San Francisco, CA
Format: Corporate Presentation
In addition to the presentation, company management will be available to participate in one-on-one meetings with investors who are registered attendees of the conference. A webcast of the presentation will be available on the Investor’s section of the company’s website at www.atyrpharma.com. Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact investorrelations@atyrpharma.com.
About aTyr
aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr’s discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease, a group of immune-mediated disorders that can cause inflammation and progressive fibrosis, or scarring, of the lungs. For more information, please visit www.atyrpharma.com.
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
FAQ
When and where will aTyr Pharma (ATYR) present at the J.P. Morgan Healthcare Conference 2025?
What is aTyr Pharma's (ATYR) lead therapeutic candidate in development?
How can investors access aTyr Pharma's (ATYR) J.P. Morgan Healthcare Conference presentation?
What is the focus of aTyr Pharma's (ATYR) discovery platform?
What medical conditions does aTyr Pharma (ATYR) target with its therapeutics?
